首页> 美国卫生研究院文献>The British Journal of Ophthalmology >Comparative study between deep sclerectomy with and without collagen implant: long term follow up
【2h】

Comparative study between deep sclerectomy with and without collagen implant: long term follow up

机译:有无胶原蛋白植入物的深层巩膜切除术的比较研究:长期随访

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

>Aim: To identify the value of using collagen implant in deep sclerectomy.>Methods: A prospective randomised trial of 104 eyes (104 patients) with medically uncontrolled primary and secondary open angle glaucoma. All patients had deep sclerectomy (DS), half of them with and the other half without a collagen implant (CI) sutured in the scleral bed. The main outcome measures were intraocular pressure (IOP), visual acuity, number of treatments preoperative and postoperative, and Nd:YAG goniopunctures.>Results: Mean follow up period was 44.5 (SD 21) months for the DS group and 43.9 (SD 14) months for the deep sclerectomy with a collagen implant (DSCI) group. The mean preoperative IOP was 23.3 (SD 7.2) mm Hg for the DS group and 25.6 (SD 4.9) mm Hg for the DSCI group. The mean IOP at the first postoperative day was 6.1 (SD 4.21) mm Hg for the DS group and 5.1 (SD 3.3) mm Hg for the DSCI group. At 48 months IOP was reduced by 40% (14 versus 23.3 mm Hg) for the DS group and by 50% (12.7 versus 25.6 mm Hg) for the DSCI group. Complete success rate, defined as IOP lower than 21 mm Hg without medication, was 34.6% (18/52 patients) at 48 months for the DS group, and 63.4% (33/52 patients) for the DSCI group. Qualified success rate; patients who achieved IOP below 21 mm Hg with or without medication, was 78.8% (41/52 patients) at 48 months and 94% (49/52 patients) for the DSCI group. The mean number of medications was reduced from 2.1 (SD 0.8) to 1.0 (SD 1) after DS, and was reduced from 2.2 (SD 0.7) to 0.4 (SD 0.6) in the DSCI group (p = 0.001)>Conclusion: The use of a collagen implant in DS enhances the success rates and lowers the need for postoperative medication.
机译:>目标:是为了确定在深层巩膜切除术中使用胶原蛋白植入物的价值。>方法:这项前瞻性随机试验针对104眼(104例患者)的原发性和继发性开放性青光眼进行了医学控制。所有患者均进行了深层巩膜切除术(DS),其中一半在巩膜床上缝合,而另一半没有缝合胶原蛋白植入物(CI)。主要预后指标包括眼压(IOP),视力,术前和术后治疗次数以及Nd:YAG角膜穿刺术。>结果: DS的平均随访时间为44.5(SD 21)个月组和胶原植入物(DSCI)组进行深层巩膜切除术的时间为43.9(SD 14)个月。 DS组平均术前眼压为23.3(SD 7.2)mm Hg,DSCI组为25.6(SD 4.9)mm Hg。术后第一天的平均眼压为DS组为6.1(SD 4.21)mm Hg,DSCI组为5.1(SD 3.3)mm Hg。在48个月时,DS组的IOP降低了40%(14对23.3 mm Hg),而DSCI组的IOP降低了50%(12.7对25.6 mm Hg)。 DS组在48个月时的完全成功率定义为IOP低于21 mm Hg,DS组为48.6%(18/52例),DSCI组为63.4%(33/52例)。合格率;接受或不接受药物治疗,眼压低于21毫米汞柱的患者在48个月时为78.8%(41/52例),DSCI组为94%(49/52例)。 DSCI组的平均药物数量从2.1(SD 0.8)降低至1.0(SD 1),DSCI组从2.2(SD 0.7)降低至0.4(SD 0.6)(p = 0.001)>结论:在DS中使用胶原蛋白植入物可提高成功率,并减少术后药物的需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号